MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-07-2026
Nymox Pharmaceutical Corporation Revenue 2011-2026 | NYMX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5 K | 116 K | 299 K | 224 K | 284 K | 2.76 M | 2.95 M | 3.36 M | 3.07 M | 3.11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.36 M | 5 K | 1.62 M |
Quarterly Revenue Nymox Pharmaceutical Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 5 K | - | 39 K | 20 K | 30 K | - | 40 K | 88 K | 152 K | - | 31 K | 9 K | 78 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 152 K | 5 K | 49.2 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K |  USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.49 | 0.58 % | $ 1.04 B |  Canada |
 |
Frequency Therapeutics
FREQ
|
6.39 M | - | - | $ 528 M | USA |
 |
argenx SE
ARGX
|
36.4 M | $ 700.45 | -1.19 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.6 | 1.41 % | $ 8.66 B |  Australia |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 7.81 | -2.01 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 225.98 | -1.32 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
2.34 M | $ 4.13 | -5.06 % | $ 105 M |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
BioCardia
BCDA
|
477 K | $ 1.26 | -0.79 % | $ 26.7 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
167 M | $ 14.2 | -0.7 % | $ 208 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 91.19 | 1.21 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.44 | -1.37 % | $ 367 M | Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 6.68 | -4.57 % | $ 183 M |  Israel |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
42.3 M | - | - | $ 521 M | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 7.92 | 1.67 % | $ 1.31 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.54 | -5.22 % | $ 16 M | USA |
 |
Certara
CERT
|
419 M | $ 6.67 | 1.6 % | $ 1.07 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.6 | -4.0 % | $ 7.83 B | Israel |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |